Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed.
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather this year.
Analyzing the Third Quarter 2025 13F Filing PRIMECAP Management (Trades, Portfolio) recently submitted its 13F filing for the third quarter of 2025, offering a
Eli Lilly released more positive mid-stage clinical trial results for a weight management candidate. The company should dominate this area through the end of the decade, at least, despite the competit
Accredited Investors Inc. increased its position in shares of Eli Lilly and Company (NYSE: LLY) by 17.1% in the undefined quarter, according to the company in its most recent Form 13F filing with the
Eli Lilly is dropping CVS Health's drug benefit plan for its employees after CVS stopped covering its weight-loss drug in favor of a rival medication from Novo Nordisk , Bloomberg News reported on Tue
Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing a trillion-dollar valuation.
Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.

Three Healthcare Buys That Wall Street Loves

10:50am, Tuesday, 11'th Nov 2025
New technologies and an aging population are lifting the healthcare sector. Immunotherapy and anti-obesity drugs are leading the way.
In addition, according to analysts at UBS, it sees Nvidia guiding fourth quarter revenue to a range of $63 billion to $64 billion.
MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder that causes s
The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close.
Eli Lilly (LLY 1.39%) and Novo Nordisk (NVO 1.89%) agreed to lower prices for their weight loss treatments in exchange for lower tariffs and expanded access.
The watchlist stocks have bucked the market's recent volatility.
Eli Lilly delivered fantastic third-quarter results, largely thanks to tirzepatide. The company's current lineup and pipeline make the stock attractive.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE